Neuroendocrine Cancer Mobile Phone App
‘My NETs’ is a new disease-specific App that can be utilised by anyone affected by Neuroendocrine Cancer.
It can be used for day to day information gathering such as symptom tracking, managing and storing health details, (such as blood and other test results, diet and medications, appointments, etc.) and has a functionality that enables users to send data directly to their care team, through a dedicated HCP portal.
It is also supported by an accessible library of resources that include evidence-based information – in written, video and audio formats.
You can download the app on the following app store.
Select the image to be taken to your preferred app store
About the App
The App has been developed by Ampersand Health, with the support and input of the Neuroendocrine Cancer community -patients, supporters and HCP’s.
The design and development were co-funded by NCUK & UKINETs.
The App has 2 key functions:
- Firstly, as a self-management tool for the Neuroendocrine Cancer community
- Secondly as a research* tool.
The current study* is to evaluate the App’s utilisation as a means of reporting and recording patient reported outcomes (PROs) – ‘A study to assess use of mobile device technology to collect patient reported symptoms during medical and surgical therapy for neuroendocrine tumours’ – it has a number of UK centres already signed up to take part. ClinicalTrials.gov Identifier: NCT04324502 *
Feedback, about utilisation as a self-management record and tool, from those using the App is also encouraged and welcomed.
To take part in the trial – please ask your NET team.
To find out more about the developers – Ampersand Health.
Please direct all enquiries to either the study lead* or the developer Ampersand:
Where would you like to visit next?
Select the image to learn more.
About Us
Neuroendocrine Cancer UK is a UK wide charity solely dedicated to providing support and information to those affected by Neuroendocrine Cancer.
Subscribe
Subscribe to our Newsletter to stay update with our latest news.